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Purpose: Previous studies have independently provided evidence for the effects of HIV 
infection, hypothalamic–pituitary–adrenal (HPA) axis dysfunction and early life trauma on 
neurocognitive impairment (NCI). This study examined the interaction between single-nucleotide 
polymorphisms (SNPs) of two HPA axis genes, corticotrophin-releasing hormone receptor 1 
(CRHR1; rs110402, rs242924, rs7209436, and rs4792888) and corticotrophin-releasing hor-
mone-binding protein (CRHBP; rs32897, rs10062367, and rs1053989), childhood trauma, and 
HIV-associated NCI.
Patients and methods: The sample comprised 128 HIV-positive Xhosa females of whom 
88 (69%) had a history of childhood trauma. NCI was assessed using a battery of 17 measures 
sensitive to the effects of HIV, and the history of childhood trauma was assessed using the 
validated retrospective Childhood Trauma Questionnaire-Short Form. Generalized linear 
regression models were used to compare allelic distribution by trauma status and global NCI. 
The association between genotype, childhood trauma, and cognitive scores was also evalu-
ated using generalized linear regression models, assuming additive models for the SNPs, 
and ANOVA.
Results: Of the seven polymorphisms assessed, only the rs10062367 variant of CRHBP was 
significantly associated with global NCI (P=0.034), independent of childhood trauma. This 
polymorphism was not significantly associated with z-scores on any specific cognitive domain. 
The interaction of childhood trauma and variants of CRHR1 was associated with poorer learning 
(rs110402) and/or recall (rs110402 and rs4792888).
Conclusion: These findings suggest that CRHBP rs10062367 A allele is a possible risk variant 
for NCI in HIV, independent of childhood trauma. Furthermore, results show that the inter-
action of childhood trauma with variants of CRHR1, rs110402 and rs4792888, confer added 
vulnerability to NCI in HIV-infected individuals in cognitive domains that are known to be 
impacted by HIV. While these findings need independent replication in larger samples, it adds 
CRHBP and CRHR1 to the list of known genes linked to HIV- and childhood trauma-associated 
neurocognitive phenotypes.
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Introduction
In South Africa, the number of people living with HIV is estimated to be about 7.06 
million (which is 12.6% of the total population) and includes more than one-fifth of all 
women aged 15–49 years.1 South African women are disproportionately affected by 
HIV, and many also have trajectories characterized by trauma over the life course.2–5 
Trauma has been associated with impaired neurocognitive functioning, as well as 
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the development of various psychopathologies, including 
major depressive disorder (MDD) and posttraumatic stress 
disorder.5,6 The effects of early life trauma may exacerbate 
the neurocognitive deficits caused by HIV infection.
HIV infection is associated with neurological and 
neurocognitive complications, collectively referred to as 
HIV-associated neurocognitive disorders (HAND). HAND 
describes a spectrum of disorders ranging from asymptom-
atic neurocognitive impairment (ANI), an intermediate form 
termed mild neurocognitive disorder (MND), to a severe 
form which constitutes HIV-associated dementia (HAD).7 
The precise pathophysiology of neurocognitive impairment 
(NCI) in HIV-positive patients is not entirely clear, although 
it appears that only certain subsets of neurons and subpopu-
lations of patients appear to be affected by HIV-induced 
central nervous system (CNS) injury, and both host and viral 
factors are important.8
The development of HAND negatively impacts social 
and occupational functioning, quality of life, and medica-
tion adherence.9,10 However, since the introduction of highly 
active antiretroviral therapy (HAART), the pattern of HAND 
appears to have radically changed. In particular, there has 
been a significant reduction in HAD with an increased preva-
lence of ANI and MND.7 Although less devastating than 
HAD, milder forms of HAND adversely impact important 
outcomes, including medication adherence and performance 
of cognitively demanding activities of daily living.11,12 It is 
still unclear why NCI persists in the post combined antiret-
roviral therapy (cART) era. Possible reasons include cardio-
vascular disease risk factors,13 immune system activation and 
inflammation,14–16 genetic factors,8,17 antiretroviral therapy 
neurotoxicity,18 substance abuse,19 advancing age,20 HIV 
reservoirs within the CNS,21 and chronic dysfunction of the 
hypothalamic–pituitary–adrenal (HPA) axis.22
The HPA axis is the primary regulator of environmental 
stress in humans. Stress triggers the release of corticotrophin- 
releasing hormone (CRH) which activates the HPA axis 
by binding to the corticotrophin-releasing hormone recep-
tor 1 (CRHR1) in the anterior pituitary. The resultant 
neuroendocrine cascade culminates in the production of 
cortisol, which mediates the restoration of homeostasis.23 
Aberrant HPA axis regulation has been associated with 
hippocampal atrophy, cognitive deficits, and a number of 
psychiatric disorders.24–26 HPA axis dysregulation occurs 
during the course of HIV infection due to a chronic increase 
in basal endogenous cortisol levels.22,27–29 Other possible 
mechanisms by which HIV may cause HPA axis dysfunction 
include chronic stress,30,31 direct CNS invasion and 
damage, secondary effects of cytokines, and side effects of 
antiretroviral therapy.32,33
Chronic dysregulation of the HPA axis has also been 
noted in several stress-related psychiatric disorders, espe-
cially in individuals traumatized in childhood.34–37 Therefore, 
early life trauma might, via its effect on the HPA axis, exac-
erbate NCI in HIV-positive patients. However, as genetic 
factors also play a significant role in the development of 
psychopathology following trauma exposure,38 examining 
genetic influences on this susceptibility may aid in identify-
ing individuals most vulnerable to HAND and facilitate more 
targeted therapeutic and preventive interventions.
Genetic polymorphisms that could affect the function 
of genes known to regulate the HPA axis are considered 
likely determinants of the link between stress responsivity 
and risk for psychopathology.39 One way in which the HPA 
axis is regulated is by the CRH-binding protein (CRHBP), 
which binds CRH with high affinity making it unavail-
able for binding with the CRH type 1 receptor (CRHR1).40 
CRHR1 and CRHBP gene variants have been associated 
with a number of clinical phenotypes, including MDD41 and 
behavioral inhibition.42 Bradley et al also showed that two 
CRHR1 single-nucleotide polymorphisms (SNPs; rs110402 
and rs7209436) interacted with childhood maltreatment to 
predict depressive symptoms in adulthood.43 In each case, 
maltreatment was associated with increased depression 
in carriers of a common allele (G for rs110402 and C for 
rs7209436), while carriers of the rare allele (A for rs110402 
and T for rs7209436) showed no increase in depressive 
symptoms compared to controls. Similarly, variations in 
three CRHBP SNPs (rs6453267, rs7728378, and rs10474485) 
may predispose to suicidal behavior in individuals who have 
experienced childhood trauma.44 Polymorphisms of genes in 
the CRH system have been associated with glucocorticoid 
resistance and reduced negative feedback of the HPA axis,45 
as well as cortisol reactivity.46
In summary, genetic factors, childhood trauma, and 
HPA axis dysfunction might all be pathognomonic mech-
anisms and potentially interact in the development of 
psychopathology in individuals with HIV. To the best of 
our knowledge, no previous study has investigated the 
combination of these factors as possible determinants 
in the development of HAND. Spies et al previously 
reported on the independent and additive effects of HIV 
and early trauma in South African women.47 Therefore, 
using data from this same cohort, the aim of the current 
study was to assess the relationship between polymorphic 
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This study involved analysis of data from participants 
recruited as part of the Biological Endophenotypes of HIV 
and Childhood Trauma (BEHCT) study conducted at Stel-
lenbosch University, Cape Town. The aim of the BEHCT 
study was to assess the genetic, cognitive, and neuroimaging 
outcomes in HIV-positive women. This study utilizes an adult 
female cohort (18–65 years), recruited between 2008 and 
2013, with samples genotyped in 2017. The study design, 
data collection methods, and the inclusion/exclusion criteria 
for the BEHCT study have been described previously.27 The 
main procedures applicable to the current study are briefly 
outlined below.
study sample
Out of 140 eligible women, 12 (9%) were excluded from 
this study as genotyping data for these participants were 
not available. Therefore, a total of 128 HIV-positive, 
Black African Xhosa women who had full genetic and 
neurocognitive data were included in the present study. 
This particular demographic was chosen to reduce genetic 
heterogeneity. Eligibility criteria included willingness and 
ability to provide written informed consent, ability to read 
and write in either English or isiXhosa at fifth-grade level, 
aged between 18 and 65 years, and medically well enough 
to undergo neuropsychological testing. Exclusion criteria 
comprised a current or past history of schizophrenia, bipolar 
disorder, or other psychotic disorders; current substance 
or alcohol abuse or dependence; significant previous head 
injury; demonstrated frank dementia on the HIV dementia 
scale; current seizure disorders of any cause; history of 
CNS infections or neoplasms; hepatitis B-positive status; 
and current use within the last month of any psychotropic 
medication.
Demographic, clinical, and psychological 
characteristics
Age, gender, marital status, ethnicity, years of education, 
and employment status were captured by questionnaires, 
while virologic markers of HIV infection (CD4 lympho-
cyte counts) were obtained from blood samples. Current 
and lifetime psychiatric disorders were evaluated using 
the MINI International Neuropsychiatric Interview-Plus 
(MINI-Plus).48 Depressive and trauma symptomatology 
were assessed using the Center for Epidemiologic Studies 
Depression Scale (CES-D) and the Davidson Trauma Scale, 
respectively.49,50
childhood trauma and neurocognitive 
assessment
Histories of abuse and neglect were assessed using the 
Childhood Trauma Questionnaire-Short Form (CTQ-SF), a 
28-item self-report inventory that provides valid screening 
for histories of abuse and neglect.51 The tool assesses five 
types of maltreatment including emotional, physical, and 
sexual abuse and emotional and physical neglect. Each of 
these five subscales consists of five items, each of which is 
scored from 5 to 25. Therefore, the total score ranges from 
25 to 125 and higher scores reflect higher levels of childhood 
trauma. In particular, 25–31 = no trauma, 41–51 = low-to 
moderate, 56–68 = moderate-to-severe, and 73–125 = severe-
to-extreme. Similar to Spies et al,47 we used a score $41 to 
identify trauma-exposed individuals, as this represents the 
lowest level score indicative of abuse or neglect (ie, low to 
moderate) for each subscale.
NCI was assessed using a battery of 17 tests that are 
sensitive to the effects of HIV infection. This battery was 
originally developed by the HIV Neurobehavioral Research 
Center at the University of California, San Diego, and has 
been culturally adapted for the South African context, as 
described by Spies et al.52 Childhood trauma and neurocogni-
tive assessments were performed by trained researchers and 
were conducted in either English or isiXhosa.
genotyping
DNA was extracted from whole blood using phenol-
chloroform extraction. Genotyping was conducted by LGC 
Genomics (United Kingdom). Validated SNPs with a minor 
allele frequency of .0.2 in at least one African population 
genotyped for the Hapmap project (www.hapmap.org), and 
which have been previously associated with some aspects of 
neuro-psychopathology, were selected for investigation.43,44,53 
We genotyped four CRHR1 SNPs (CRHR1; rs110402 (C to T) 
[n=127], rs242924 (C to A) [n=127], rs7209436 (C to T) 
[n=122], and rs4792888 (G to A) [n=122]) and three CRHBP 
SNPs (CRHBP; rs32897 (G to A) [n=122], rs1053989 (C to A) 
[n=126], and rs10062367 (G to A) [n=124]). Pair-wise link-
age disequilibrium (LD) for the SNPs (Figure 1) was esti-
mated using the solid spline method in Haploview, version 
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Demographic and clinical characteristics of study participants 
were summarized as counts and percentages for dichotomous 
traits, and means and SD or medians and 25th–75th percen-
tiles (interquartile range) for quantitative traits.
Age- and education-corrected z-scores were calculated from 
all raw neuropsychological data and grouped into domains 
(motor function, verbal fluency, attention/working memory, 
speed, learning, recall, and executive functions). This was done 
by running a regression analysis on all raw neuropsychological 
data using test scores as the outcome and age and education 
as predictors. The residual was then saved, and a studentized 
residual was calculated. Within each domain, the studentized 
residual for each test was summed to obtain a domain z-score. 
Global NCI scores represent the mean of individual cognitive 
domain scores.
The Shapiro–Wilk W test was used to test for normality. 
Differences in normally distributed demographic and clinical 
variables (age, global NCI scores, NCI domain scores for 
verbal fluency, attention/working memory, speed, learning, 
recall, and executive functions) according to trauma status 
were determined using Student’s t-test, while differences in 
non-parametric variables (CTQ scores, CES-D scores, viral 
load, CD4 counts, and NCI domain scores for motor func-
tion) were determined using Welch’s unequal variances t-test. 
Pearson’s chi-squared test was used to assess the relationship 
between categorical variables.
The contribution of each SNP to global NCI scores was 
evaluated using generalized linear regression models. When 
the results were significant, additional generalized linear 
regression models were used to evaluate the contribution of 
the SNP to individual cognitive domain scores. Generalized 
linear models, assuming additive models for the SNPs, were 
also used to evaluate if there was any association between 
genotype and CTQ scores, as well as to investigate the rela-
tionships between genotype, childhood trauma, and cognitive 
scores. Finally, analysis of variance (ANOVA) was used to 
determine whether including the interaction between geno-
type × childhood trauma explained more of the variance in 
cognitive domain scores than these two predictors acting indi-
vidually. Antiretroviral (ARV) treatment and CES-D scores 
were included as covariates in the regression models.
Analyses were carried out using R statistical software 
version 3.2.2 (The R Foundation for Statistical Computing, 
Vienna, Austria) with the R package SNPassoc.55 Statistical 
significance was set at P,0.05.
ethical considerations
The study was approved by the Health Research Ethics Com-
mittee (HREC # N07/07/153A) of Stellenbosch University 
(Cape Town, South Africa). All participants gave written 
informed consent for participation according to locally and 
internationally accepted ethical guidelines. Participation in 
the present study was entirely voluntary and participants 
were informed of their right to withdraw their participation 
at any point in the study. Women who required further care 
were referred to their local community health care facility. 
Participants were reimbursed for their transport costs to 
attend study visits.
Results
Table 1 shows demographic and clinical variables for the over-
all sample and by trauma status. Of the 128 participants, 88 
(69%) had a history of childhood trauma. Those participants 
with childhood trauma had higher self-reported depression on 
the CES-D. This converged with interviewer-based assess-
ment of psychopathology using the MINI-Plus, with a sig-
nificantly greater proportion in the childhood trauma-exposed 
group meeting diagnostic criteria for recurrent MDD.
Less than half the sample (41.4%) were on ARVs. ARV 
status had no significant impact on cognitive domain scores, 
except for the recall domain (Table 2).
Regression analysis revealed that individuals carrying 
at least one CRHBP rs10062367 G allele had significantly 
higher global NCI z-scores compared to subjects homozygous 
Figure 1 haplotype block structure for CRHBP and CRHR1.
Note: The numbers in the squares refer to pairwise linkage disequilibrium (lD) 
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hPa-axis genes as potential risk variants for neurocognitive decline
Table 1 Demographic and clinical characteristics of study participants (n=128) showing differences between those with/without 
childhood trauma exposure
Variable Overall (n=128) Childhood trauma exposure
No (n=40) Yes (n=88) T χ2 P-value
Mean age in years (sD) 33.2 (6.8) 32.0 (6.8) 33.7 (6.8) -1.33 – 0.19
Mean years of education (sD) 10.1 (1.7) 10.5 (1.3) 10.0 (1.8) 1.70 0.09










Unemployed 85 (66.4) 24 (60.0) 61 (69.3) 1.070 0.32
Median cD4 T lymphocyte count (iQr) 396.0 (237.8–587.5) 347.0 (195.3–587.5) 416.0 (259.5–604.8) -0.94 – 0.35
On arVs, n (%) 58 (41.4) 14 (31.1) 41 (46.3) – 1.508 0.25
Median cTQ-sF (iQr) 53.0 (37.5–70.5) 325.5 (29–36) 61.5 (53–77.75) -18.09 – ,0.01
Depression (MDD, single), n (%) 6 (5) 0 (0) 6 (7) 0.09
Depression (MDD, recurrent), n (%) 9 (7) 0 (0) 9 (10) 0.04*
Median ces-D total score (iQr) 8.5 (0–27) 4 (0–11.75) 14 (0–48.1) -3.70 – ,0.01
Notes: *Indicates a significant chi-squared or t-test at P,0.05.
Abbreviations: arV, antiretroviral; cD4, cluster of differentiation 4 glycoprotein; ces-D, center for epidemiologic studies Depression scale; cTQ-sF, childhood Trauma 
Questionnaire - short form; MDD, major depressive disorder, single or recurrent episode; iQr, interquartile range.
Table 2 Differences in mean global Nci scores (z-scores) by arT status
Neurocognitive  
domain
Mean NCI z-scores (± SD) T value df P-value
ARVs No ARVs
Motora -0.159 (1.500) 0.097 (0.700) -1.170 69.8 0.246
Verbal fluency -0.101 (0.802) -0.204 (0.761) 0.743 126 0.459
Working memory -0.067 (0.735) -0.090 (0.959) 0.143 126 0.886
speed -0.076 (0.731) -0.018 (0.679) -0.463 126 0.644
learning -0.172 (0.870) 0.067 (0.827) -1.578 126 0.117
recall -0.235 (0.938) 0.063 (0.733) -2.017 126 0.046*
executive functions -0.157 (0.827) 0.078 (0.546) -1.934 126 0.055
global -0.125 (0.577) -0.011 (0.533) -1.157 126 0.250
Notes: aNot normally distributed. Median scores (iQr) for this domain: Not on arT = 0.241 (-0.284 to 0.550); participants on arV = 0.278 (-0.425 to 0.702). *indicates 
a significant t-test at P,0.05.
Abbreviations: arT, antiretroviral therapy; arV, antiretroviral; iQr, interquartile range; Nci, neurocognitive impairment.
for the A allele (Table 3). On further analysis, this poly-
morphism was not significantly associated with z-scores on 
specific cognitive domains.
There were no significant differences in childhood trauma 
CTQ-SF scores across genotypes. In addition, childhood 
trauma status was not significantly associated with global NCI 
(P=0.441) or specific domain scores (motor function: P=0.089, 
verbal fluency: P=0.894, attention/working memory: P=0.458, 
processing speed: P=0.430, learning: P=0.785, recall: 
P=0.238, executive function: P=0.996). However, cognitive 
domain z-scores were influenced by the interaction between 
childhood trauma and polymorphisms in CRHR1. In particu-
lar, the presence of at least one T allele in CRHR1 rs110402 
interacted with childhood trauma to worsen learning and recall. 
In contrast, the presence of at least one C allele in CRHR1 
rs7209436 interacted with childhood trauma to improve learn-
ing and recall. Finally, the presence of at least one A allele in 
rs4792888 interacted with childhood trauma to worsen recall 
(Table 4).
Discussion
We evaluated the interaction between childhood trauma, 
variants of two HPA-axis genes, CRHBP and CRHR1, and 
NCI in a sample of Black African Xhosa women living 
with HIV. Of the seven polymorphisms assessed, only the 
rs10062367 variant of CRHBP was significantly associated 
with NCI, independent of childhood trauma. Compared to 
carriers of the rs10062367 G allele, A homozygotes had 
significantly lower global NCI scores. However, this poly-
morphism was not significantly associated with z-scores on 
specific cognitive domains. Host genetic factors have been 
found to predispose HIV-infected individuals to NCI.56,57 
To the best of our knowledge, CRHBP rs10062367 has not 
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our findings, while requiring further independent replica-
tion in a larger sample, may be the first to suggest a pos-
sible link between rs10062367 and NCI in HIV-infected 
individuals.
The lack of an association between NCI and other variants 
of CRHBP suggest an independent effect of rs10062367 on 
global neurocognitive deficits, or the effect of another poly-
morphism in LD with rs10062367. Other plausible reasons 
for the lack of a significant association between other SNPs 
and NCI may be the limited number of CRHBP polymor-
phisms that we assessed and the relatively small sample of 
HIV-infected participants.
In the current study, the interaction of childhood trauma 
and CRHR1 variants was associated with poorer learning 
(rs110402) and/or recall (rs110402 and rs4792888). Early-
life trauma has been associated with impaired neurocognitive 
functioning,6,47 and previous studies have demonstrated an 
association between childhood trauma and polymorphisms 
in CRHR1 and CRHBP in non-HIV samples.43,44 There may 
be a few reasons why trauma did not interact with CRHBP 
gene variants in contributing to NCI in HIV-infected indi-
viduals. Firstly, the rs10062367 CRHBP variant might 
confer vulnerability to NCI independent of environmental 
stress exposure, at least in this population. Various CRHBP 
polymorphisms have previously been associated with psy-
chopathology including suicidality and anxiety,44,58–61 with 
emerging evidence also indicating that variants of the CRHBP 
gene (eg, rs28365143) can robustly predict pharmacotherapy 
outcomes in depression (ie, symptom change, response, and 
remission).61,62 Nevertheless, results show that the interaction 
of childhood trauma with variants of CRHR1, specifically 
rs110402 and rs4792888, confer added vulnerability to neu-
rocognitive decline in HIV-infected individuals.
A possible limitation of this study was that childhood 
trauma was assessed retrospectively and is, as such, prone to 
recall bias. Moreover, there are potential confounding vari-
ables which we did not control for, namely, 1) the possible 
trauma of contracting HIV and/or an effect of HIV infection 
overriding any effect(s) of childhood trauma, 2) any effect(s) 
of adult-onset trauma, 3) viral load and ARV regimen differ-
ences between the groups (there were, however, no signifi-
cant differences in CD4 count between trauma exposed and 
unexposed groups), and 4) the higher level of self-reported 
depression in the childhood trauma group. Another limita-
tion is that our sample included only Black African women 
living with HIV and we, therefore, cannot generalize our 
findings to HIV-uninfected individuals, other races or ethnic 
groups, or to HIV-infected males. Finally, this was a relatively 
small sample, and larger sample replication studies would be 
helpful to validate these findings.
Table 3 Differences in neurocognitive impairment (z-scores) 
across genotypes for CRHBP rs10062367
Genotype Frequency,  
n (%)
Neurocognitive impairment
z-score (± SD) P-value
codominant 0.106
g/g 40 (32.26) 0.00551 (±0.592)
g/a 57 (45.97) -0.00474 (±0.554)
a/a 27 (21.77) -0.25484 (±0.454)
Dominant 0.396
g/g 40 (32.26) 0.00551 (±0.592)
g/a-a/a 84 (67.74) -0.08513 (±0.534)
recessive 0.034*
g/g-g/a 97 (78.23) -0.00052 (±0.567)
a/a 24 (19.35) -0.25484 (±0.454)
additive 0.080
Note: *Indicates statistical significance at P,0.05.
Table 4 Predictive value of CRHR1 variants × childhood trauma interactions on cognitive domain scores
Interaction df Deviance residual df residual Deviance P (.χ2)
learning
rs110402 + cTQ 122 88.690
rs110402 + cTQ + rs110402*cTQ 121 85.212 1 3.478 0.03
rs7209436 + cTQ 123 88.864
rs7209436 + cTQ + rs7209436*cTQ 122 85.502 1 3.362 0.03
recall
rs110402 + cTQ 122 84.998
rs110402 + cTQ + rs110402*cTQ 121 79.703 1 5.295 0.01
rs7209436 + cTQ 123 85.273
rs7209436 + cTQ + rs7209436*cTQ 122 80.158 1 5.114 0.01
rs4792888 + cTQ 123 85.943
rs4792888 + cTQ + rs4792888*cTQ 122 82.918 1 3.025 0.04
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hPa-axis genes as potential risk variants for neurocognitive decline
Future studies should ideally include data from HIV-
negative controls (unexposed to either child or adult trauma) 
and consist of larger sample sizes. There is also a need to 
investigate the functional effects these particular CRH1 and 
CRHBP SNPs. Moreover, to further interrogate the CRHBP 
rs10062367 genotype and stress response abnormalities, 
future studies could investigate HPA-axis neuroendocrine 
endophenotypes of NCI (eg, cortisol). Future studies should 
also take duration63 and type53 of trauma into account as these 
trauma variables can impact NCI.
Conclusion
The study shows that HPA-axis genes are possible risk vari-
ants for NCI among HIV-infected women and may interact 
with childhood trauma to impact specific domains of cog-
nitive function. The combination of these vulnerabilities 
might be early markers of NCI in HIV-infected individuals 
and might represent potential targets for therapeutic action. 
However, replication studies involving whole gene-based 
association analyses of SNPs in CRHBP, as well as a more 
detailed analysis of childhood trauma, are needed.
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